Traffic lights for retinoids in oncology: molecular markers of
retinoid resistance and sensitivity and their use in the
management of cancer differentiation therapy

J 2018

Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy

DOBROTKOVÁ, Viera, Petr CHLAPEK, Pavel MAZÁNEK, Jaroslav ŠTĚRBA, Renata VESELSKÁ et. al.

Základní údaje

Originální název

Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy

Autoři

DOBROTKOVÁ, Viera (703 Slovensko, domácí), Petr CHLAPEK (203 Česká republika, domácí), Pavel MAZÁNEK (203 Česká republika, domácí), Jaroslav ŠTĚRBA (203 Česká republika, domácí) a Renata VESELSKÁ (203 Česká republika, garant, domácí)

Vydání

BMC Cancer, London, BioMed Central, 2018, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.933

Kód RIV

RIV/00216224:14310/18:00106966

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1186/s12885-018-4966-5

UT WoS

000449121200004

Klíčová slova anglicky

Retinoids; cell differentiation; retinoid resistance; retinoid sensitivity; predictive biomarkers; acute myeloid leukemia; pancreatic ductal adenocarcinoma; breast carcinoma; neuroblastoma

Štítky

14110321, podil

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 2. 2019 16:19, prof. RNDr. Renata Veselská, Ph.D., M.Sc.

Anotace

V originále

For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have reported the promising role of retinoids in attaining better outcomes for adult or pediatric patients suffering from several types of cancer, especially acute myeloid leukemia and neuroblastoma. However, even this promising differentiation therapy has some limitations: retinoid toxicity and intrinsic or acquired resistance have been observed in many patients. Therefore, the identification of molecular markers that predict the therapeutic response to retinoid treatment is undoubtedly important for retinoid use in clinical practice. The purpose of this review is to summarize the current knowledge on candidate markers, including both genetic alterations and protein markers, for retinoid resistance and sensitivity in human malignancies.

Návaznosti

NV15-34621A, projekt VaV

Název: Kandidátní biomarkery rezistence k retinoidům u dětí s vysoce rizikovými neuroblastomy

Citovat

DOBROTKOVÁ, Viera, Petr CHLAPEK, Pavel MAZÁNEK, Jaroslav ŠTĚRBA a Renata VESELSKÁ. Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. BMC Cancer. London: BioMed Central, 2018, roč. 18, č. 1059, s. nestránkováno, 13 s. ISSN 1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-018-4966-5.

@article{1490216,
   author = {Dobrotková, Viera and Chlapek, Petr and Mazánek, Pavel and Štěrba, Jaroslav and Veselská, Renata},
   article_location = {London},
   article_number = {1059},
   doi = {http://dx.doi.org/10.1186/s12885-018-4966-5},
   keywords = {Retinoids; cell differentiation; retinoid resistance; retinoid sensitivity; predictive biomarkers; acute myeloid leukemia; pancreatic ductal adenocarcinoma; breast carcinoma; neuroblastoma},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy},
   url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5},
   volume = {18},
   year = {2018}
}

TY  - JOUR
ID  - 1490216
AU  - Dobrotková, Viera - Chlapek, Petr - Mazánek, Pavel - Štěrba, Jaroslav - Veselská, Renata
PY  - 2018
TI  - Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
JF  - BMC Cancer
VL  - 18
IS  - 1059
SP  - nestránkováno
EP  - nestránkováno
PB  - BioMed Central
SN  - 14712407
KW  - Retinoids
KW  - cell differentiation
KW  - retinoid resistance
KW  - retinoid sensitivity
KW  - predictive biomarkers
KW  - acute myeloid leukemia
KW  - pancreatic ductal adenocarcinoma
KW  - breast carcinoma
KW  - neuroblastoma
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5
L2  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5
N2  - For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have reported the promising role of retinoids in attaining better outcomes for adult or pediatric patients suffering from several types of cancer, especially acute myeloid leukemia and neuroblastoma. However, even this promising differentiation therapy has some limitations: retinoid toxicity and intrinsic or acquired resistance have been observed in many patients. Therefore, the identification of molecular markers that predict the therapeutic response to retinoid treatment is undoubtedly important for retinoid use in clinical practice. The purpose of this review is to summarize the current knowledge on candidate markers, including both genetic alterations and protein markers, for retinoid resistance and sensitivity in human malignancies.
ER  -

DOBROTKOVÁ, Viera, Petr CHLAPEK, Pavel MAZÁNEK, Jaroslav ŠTĚRBA a Renata VESELSKÁ. Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. \textit{BMC Cancer}. London: BioMed Central, 2018, roč.~18, č.~1059, s.~nestránkováno, 13 s. ISSN~1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-018-4966-5.

Podrobný výpis o publikaci